Neoadjuvant behandling øker andelen komplett patologisk respons ved HER2-positiv brystkreft
/ Bjørn Naume / Jan Andreasen
T-DXd in Patients with High-Risk HER2-Positive Early Breast Cancer – Are We Ready to Change Practice?
/ Henrik Lindman / Jan Andreasen
DESTINY-Breast11 and Neoadjuvant T-DXd: Insights from Finland
/ Maria Sundvall / Jan Andreasen
ESMO 2025: HER2-Targeted Therapy Advances in BTC
/ Teresa Macarulla
ESMO 2025: Nye data styrker potensialet for CDK4/6-hemmere ved tidlig brystkreft - Intervju med overlege Egil Støre Blix
/ Egil Støre Blix / Jan Andreasen
Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study
/ Igle Jan de Jong / Jan Andreasen











